Stoke Therapeutics
STOK
133 hedge funds and large institutions have $744M invested in Stoke Therapeutics in 2025 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 51 increasing their positions, 33 reducing their positions, and 16 closing their positions.
76% more capital invested
Capital invested by funds: $422M → $744M (+$322M)
55% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 33
44% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 16
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
6% more funds holding
Funds holding: 126 → 133 (+7)
2.85% more ownership
Funds ownership: 117.2% → 120.06% (+2.9%)
95% less call options, than puts
Call options by funds: $35K | Put options by funds: $672K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$46.2M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$8.39M |
| 3 |
Corient Private Wealth
Miami,
Florida
|
+$6.26M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.49M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ST
Skorpios Trust
Limassol,
Cyprus
|
-$34.7M |
| 2 |
CC
Checkpoint Capital
San Francisco,
California
|
-$4.86M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$4M |
| 4 |
Goldman Sachs
New York
|
-$3.42M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$2.22M |
STOK Hedge Fund Activity: Q2 2025 in Review
133 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q2 2025, worth a combined $744M — up 76% from $422M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new STOK positions and 16 closed out — a net gain of 7 holders — while 51 added to existing stakes and 33 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $46.2M. The largest seller was Skorpios Trust, cutting an estimated $34.7M.
- 133 institutional investors held Stoke Therapeutics (STOK) as of Q2 2025, up from 126 in Q1 2025.
- Funds reported $744M of Stoke Therapeutics stock for Q2 2025, up 76% quarter-over-quarter.
- 23 funds opened new Stoke Therapeutics positions in Q2 2025 and 16 closed out, a net change of +7 holders.
- The largest Stoke Therapeutics buyer in Q2 2025 was Fidelity Investments, an estimated $46.2M added.
- The largest Stoke Therapeutics seller in Q2 2025 was Skorpios Trust, an estimated $34.7M sold.
Based on aggregated 13F filings for Q2 2025.